Showing 1 posts of 1 posts found.
Elacestrant is the first tailored treatment for certain people with oestrogen receptor (ER)-positive HER2-negative locally advanced and metastatic breast cancer …
Dermatology leader Doncker is new Onicor CEO
East London pharmacies pilot cholesterol-lowering injections to cut waiting times
Weber is new CMO at Sensorion
Charity commits £800,000 to AI research into late breast cancer recurrence
AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over